FDA accepts sNDA for Astellas-Medivation’s prostate cancer drug XTANDI
The sNDA application was granted Priority Review designation with a stated FDA Prescription Drug User Fee Act (PDUFA) review date of 18 September 2014. Currently, XTANDI is approved
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.